骨架跃迁在药物发现中的应用

骨架跃迁概述

药物发现的总体目标是快速鉴定新化合物，这些化合物对与疾病相关的预先选定的生物靶点具有足够的安全性和类药物特性。骨架跃迁是现代药物化学合理设计药物的中心任务，被药物化学家广泛用于寻找具有新骨架和改善已知苗头化合物分子性质的等价化合物。骨架跃迁中最常用的方法包括基于结构的跃迁(图1)^[1,2]，杂环替换(图2)^[3]，环打开(图3)^[4]或环闭合(图4)^[4]，等等。

02

图2 用杂环替代法发现一种新的JAK1抑制剂

03

图3. 使用开环方法发现新的酪氨酸激酶抑制剂

04

图4. 使用环闭合方法发现新的前列腺素EP1受体拮抗剂

01

03

04

05

06

07

08

[1] Discovery of Benzoazepinequinoline (BAQ) Derivatives as Novel, Potent, Orally Bioavailable Respiratory Syncytial Virus Fusion Inhibitors. Xiufang Zheng, Chungen Liang, Lisha Wang, Hongying Yun et al. J. Med. Chem. 2018, 61, 22,10228–10241.

[2] Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor. Xiufang Zheng, Lu Gao, Lisha Wang, Hongying Yun et al. J. Med. Chem. 2019, 62, 13, 6003–6004.

[3] Contributions of intestine and liver to the absorption and disposition of FZJ-003, a selective JAK1 inhibitor with structure modification of filgotinib. Yu Zhuang et al. Eur. J. Pharm. Sci. 2022, 175, 106211-106219.

[4] Classification of Scaffold Hopping Approaches. Hongmao Sun et al. Drug Discov Today. 2012, 17, 310-324.

[5] Mastalerz, Harold; Wittman, Mark D.; Zimmermann, Kurt; Saulnier, Mark G.; Parthi, Upender; Vyas, Dolatrai M.;Zhang, Guifen; Johnson, Walter Lewis; Frennesson, David B.; Sang, Xiaopeng; Liu, Peiying; Langley, David R.; Pyrrolotriazine kinase inhibitors. WO2008005956 A2,2008

[6] Corbett, Jeffrey Wayne; Elliott, Richard Louis; Freeman-Cook, Kevin Daniel; Griffith, David Andrew; Phillion, Dennis Paul; Pyrazolospiroketone acetyl-CoA carboxylase inhibitors. WO2009144554 A1, 2009

[7] CN112457235, 2021

[8] Zhu, Yongqiang; Liu, Zhaogang; Feng, Chao; Chen Hao; Xu, Kaikai; Wang, Jia; Shi, Jingmiao; Heteroaromatic ring compound as RET kinase inhibitor, and preparation and use thereof. WO2022037643 A1, 2022

[9] European Journal of Medicinal Chemistry. 2020, 190, 112092.

[10] Reynolds, Mark; Eary, Charles Todd; Formulations comprising 6-(2-hydroxy-2- methylpropoxy)-4- (6-(6-((6- methoxypyridin-3-yl)methyl)-3,6-diazab icyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo[1,5-a]pyridine-3-carbonitrile. WO2019075114 A1, 2019

[11] Cui, Jingrong J.; Rogers, Evan W.;Diaryl macrocycle polymorph. WO2017007759 A1, 2017

[12] Xi, Ning; Li, Minxiong; Li, Xiaobo; Substituted heteroaryl compounds and methods of use. WO2015073267 A1, 2015

[13] Jin, Yunzhou; Bu, Ping; He, Qi; Lan, Jiong; Zhou, Fusheng; Zhang, Liang; He, Xiangyu; Azabicyclo derivatives, process for preparation thereof and medical use thereof. WO2016050165 A1, 2016

[14] Organic Letters. 2021, 23(12), 4694-4698

[15] Bourque, Elyse Marie Josee; SK-Erlj, Renato; CXCR4 inhibitors and uses thereof. WO2017223239 A1, 2017

[16] Swami, Archana; Rakshe, Vishal; Prodeus, Aaron; Maetani, Micah; Parmar, Rubina Giare; Lipid nanoparticle compositions. WO2022221697 A1, 2022

[17] ACS Medicinal Chemistry Letters. 2015,6(1), 37-41